Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
MEASUREMENT OF THE DOPAMINERGIC DEGENERATION IN PARKINSONS-DISEASE WITH [I-123] BETA-CIT AND SPECT - CORRELATION WITH CLINICAL FINDINGS ANDCOMPARISON WITH MULTIPLE SYSTEM ATROPHY AND PROGRESSIVE SUPRANUCLEAR PALSY
Autore:
BRUCKE T; ASENBAUM S; PIRKER W; DJAMSHIDIAN S; WENGER S; WOBER C; MULLER C; PODREKA I;
Indirizzi:
UNIV VIENNA,NEUROL KLIN,WAHRINGER GURTEL 18-20 A-1090 VIENNA AUSTRIA UNIV VIENNA,NUCL MED CLIN A-1090 VIENNA AUSTRIA RUDOLFSTIFTUNG HOSP VIENNA AUSTRIA
Titolo Testata:
Journal of neural transmission. Supplementum
fascicolo: 50, , anno: 1997,
pagine: 9 - 24
SICI:
0303-6995(1997):50<9:MOTDDI>2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
POSITRON EMISSION TOMOGRAPHY; I-123 BETA-CIT; HEALTHY-HUMAN SUBJECTS; IN-VITRO BINDING; F-18 DOPA UPTAKE; HUMAN-BRAIN; SEROTONIN TRANSPORTERS; REUPTAKE SITES; CAUDATE-NUCLEUS; INVIVO;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
60
Recensione:
Indirizzi per estratti:
Citazione:
T. Brucke et al., "MEASUREMENT OF THE DOPAMINERGIC DEGENERATION IN PARKINSONS-DISEASE WITH [I-123] BETA-CIT AND SPECT - CORRELATION WITH CLINICAL FINDINGS ANDCOMPARISON WITH MULTIPLE SYSTEM ATROPHY AND PROGRESSIVE SUPRANUCLEAR PALSY", Journal of neural transmission. Supplementum, (50), 1997, pp. 9-24

Abstract

The cocaine derivative [I-123]beta-CIT binds with high affinity to dopamine uptake sites in the striatum and can be used to visualize dopaminergic nerve terminals in vivo in the human brain with SPECT. It has been validated that the calculation of a simple ratio of specific/nondisplaceable binding during a period of binding-equilibrium in the striatum about 20 hrs after bolus injection of the tracer gives a strong and reliable index of the binding potential of dopamine uptake sites. Previous studies have shown that the dopaminergic deficit in patients with Parkinson's disease (PD) can clearly be visualized and quantified using this method. Our own results in a group of 113 patients with PD demonstrate a 45% loss of striatal [I-123]beta-CIT binding in comparison to age corrected control values. Highly significant correlations ofSPECT findings with clinical data obtained from the UPDRS rating scale such as akinesia, rigidity, axial symptoms and activities of daily living are demonstrated, while no correlation is found with tremor. Thesignal loss in a region comprising the whole striatum ranges from 35%in Hoehn/Yahr stage I to over 72% in stage V and is highly significantly correlated to the different stages of disease severity. A comparison of [I-123]beta-CIT binding in the striatum contralaterally and ipsilaterally to the affected body side in 29 patients with hemiparkinson shows a loss of striatal binding of 41% contralaterally and 30% ipsilaterally. Results from subregional analyses in caudate and putamen showrelative sparing of the caudate nucleus in PD. Data in 9 patients with multiple system atrophy (MSA) and 4 patients with progressive supranuclear palsy (PSP) are similar to the findings in PD although the differences between caudate and putamen are somewhat less marked. These data demonstrate that the dopaminergic nerve cell loss in PD and other disorders with a dopaminergic lesion can be quantified with [I-123]beta-CIT and SPECT and that hopefully a preclinical or very early diagnosis is made possible. Such studies might also open the way for a better evaluation of neuroprotective strategies in PD. It does not seem to bepossible however to differentiate PD and MSA or PSP with this method in individual cases.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 17/09/19 alle ore 22:57:09